

Masaharu Akao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3520015/publications.pdf>

Version: 2024-02-01

104
papers

4,072
citations

172207

29
h-index

118652

62
g-index

107
all docs

107
docs citations

107
times ranked

4104
citing authors

#	ARTICLE	IF	CITATIONS
1	Two-year outcomes of more than 30,000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 202-213.	1.8	47
2	Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban—J-ELD AF Registry Subanalysis. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 691-703.	1.3	3
3	Association of inverted T wave during atrial fibrillation rhythm with subsequent cardiac events. <i>Heart</i> , 2022, 108, 178-185.	1.2	5
4	Is Progression From Paroxysmal to Sustained Atrial Fibrillation Bad News?. <i>Circulation Journal</i> , 2022, 86, 176-181.	0.7	3
5	Predicting cerebral infarction in patients with atrial fibrillation using machine learning: The Fushimi AF registry. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 746-756.	2.4	4
6	Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED Study. <i>Journal of the American Heart Association</i> , 2022, 11, e023464.	1.6	4
7	Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial. <i>Circulation</i> , 2022, 145, 718-720.	1.6	3
8	Comprehensive symptom assessment using Integrated Palliative care Outcome Scale in hospitalized heart failure patients. <i>ESC Heart Failure</i> , 2022, 9, 1963-1975.	1.4	5
9	10-Year Trends of Antithrombotic Therapy Status and Outcomes in Japanese Atrial Fibrillation Patients—The Fushimi AF Registry. <i>Circulation Journal</i> , 2022, 86, 726-736.	0.7	16
10	JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Circulation Journal</i> , 2022, 86, 1790-1924.	0.7	49
11	Fine Fibrillatory Wave as a Risk Factor for Heart Failure Events in Patients With Atrial Fibrillation: The Fushimi Atrial Fibrillation (AF) Registry. <i>Journal of the American Heart Association</i> , 2022, 11, e024341.	1.6	2
12	Impact of anemia on the clinical outcomes in elderly patients with atrial fibrillation receiving apixaban: J-ELD AF registry subanalysis. <i>IJC Heart and Vasculature</i> , 2022, 40, 100994.	0.6	2
13	Impact of Previous Stroke on Clinical Outcome in Elderly Patients With Nonvalvular Atrial Fibrillation: ANAFIE Registry. <i>Stroke</i> , 2022, 53, 2549-2558.	1.0	4
14	Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2022, 7, 583.	3.0	5
15	Prognosis of elderly non-valvular atrial fibrillation patients stratified by B-type natriuretic peptide: ELDERCARE-AF subanalysis. <i>American Heart Journal</i> , 2022, 250, 66-75.	1.2	2
16	Age-dependent risk for thromboembolism in atrial fibrillation: The Fushimi AF registry. <i>IJC Heart and Vasculature</i> , 2022, 41, 101055.	0.6	2
17	Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1584-1593.	1.8	5
18	Association of Concomitant Coronary Artery Disease With Cardiovascular Events in Patients With Atrial Fibrillation—The Fushimi AF Registry. <i>Circulation Journal</i> , 2022, 86, 1252-1262.	0.7	2

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. <i>Heart</i> , 2021, 107, 705-712.	1.2	16
20	Long-term clinical outcomes after major bleeding in patients with atrial fibrillation: the Fushimi AF registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 163-171.	1.8	8
21	Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis. <i>Heart and Vessels</i> , 2021, 36, 1035-1046.	0.5	0
22	Major adverse cardiovascular events and mortality after catheter ablation in Japanese patients with atrial fibrillation: The Fushimi AF Registry. <i>Heart and Vessels</i> , 2021, 36, 1219-1227.	0.5	6
23	Background characteristics and anticoagulant usage patterns of elderly non-valvular atrial fibrillation patients in the ANAFIE registry: a prospective, multicentre, observational cohort study in Japan. <i>BMJ Open</i> , 2021, 11, e044501.	0.8	3
24	Characteristics and clinical outcomes in atrial fibrillation patients classified using cluster analysis: the Fushimi AF Registry. <i>Europace</i> , 2021, 23, 1369-1379.	0.7	12
25	Local abnormal atrial activity related to right septal intra-atrial reentrant tachycardia after mitral valve surgery. <i>HeartRhythm Case Reports</i> , 2021, 7, 203-206.	0.2	0
26	Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1757-1758.	0.8	3
27	Rivaroxaban monotherapy versus combination therapy according to patient risk of stroke and bleeding in atrial fibrillation and stable coronary disease: AFIRE trial subanalysis. <i>American Heart Journal</i> , 2021, 236, 59-68.	1.2	7
28	A Novel Risk Stratification System for Ischemic Stroke in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2021, 85, 1254-1262.	0.7	14
29	Clinical Outcomes of Very Elderly Patients With Atrial Fibrillation Receiving On-label Doses of Apixaban: J-ELD AF Registry Subanalysis. <i>Journal of the American Heart Association</i> , 2021, 10, e021224.	1.6	4
30	Prevalence, Temporal Change, and Determinants of Anxiety and Depression in Hospitalized Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, , .	0.7	6
31	Bleeding and Subsequent Cardiovascular Events and Death in Atrial Fibrillation With Stable Coronary Artery Disease: Insights From the AFIRE Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010476.	1.4	20
32	Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. <i>American Heart Journal</i> , 2021, 240, 89-100.	1.2	3
33	Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial. <i>Circulation</i> , 2021, 144, 1449-1451.	1.6	3
34	Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020907.	1.6	5
35	Clinical Characteristics and Outcomes of Very Elderly Patients With Atrial Fibrillation at High Bleeding Risk. The Fushimi AF Registry. <i>Circulation Reports</i> , 2021, 3, 629-638.	0.4	2
36	Ischemic Stroke in Acute Decompensated Heart Failure: From the KCHF Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e022525.	1.6	7

#	ARTICLE	IF	CITATIONS
37	A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). <i>Clinical Cardiology</i> , 2020, 43, 251-259.	0.7	23
38	Current status of percutaneous coronary intervention in patients with atrial fibrillation: The Fushimi AF Registry. <i>Journal of Cardiology</i> , 2020, 75, 513-520.	0.8	3
39	Impact of Smoking Status on Growth Differentiation Factor 15 and Mortality in Patients With Suspected or Known Coronary Artery Disease: The ANOX Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018217.	1.6	5
40	Cardiovascular Events and Mortality in Patients With Atrial Fibrillation and Anemia (from the Fushimi) Tj ETQq0 0 0 rgBT /Overlock 10 TF	0.7	10
41	Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2020, 383, 1735-1745.	13.9	178
42	Atrial fibrillation and stroke prevention: state of the art—epidemiology and pathophysiology: new risk factors, concepts and controversies. <i>European Heart Journal Supplements</i> , 2020, 22, O1-O13.	0.0	12
43	Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF registry sub-cohort analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1111-1124.	0.8	12
44	Impact of Valvular Heart Disease on Mortality, Thromboembolic and Cardiac Events in Japanese Patients With Atrial Fibrillation—The Fushimi AF Registry. <i>Circulation Journal</i> , 2020, 84, 714-722.	0.7	7
45	Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis. <i>American Heart Journal</i> , 2020, 223, 23-33.	1.2	8
46	Association of relative wall thickness of left ventricle with incidence of thromboembolism in patients with non-valvular atrial fibrillation: The Fushimi AF Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 273-283.	1.8	10
47	Baseline Characteristics of Elderly Japanese Patients Aged ≥75 Years With Non-Valvular Atrial Fibrillation and a History of Stroke—ANAFIE Registry. <i>Circulation Journal</i> , 2020, 84, 516-523.	0.7	1
48	Age-Related Differences in the Clinical Characteristics and Treatment of Elderly Patients With Atrial Fibrillation in Japan—Insight From the ANAFIE (All Nippon AF In Elderly) Registry. <i>Circulation Journal</i> , 2020, 84, 388-396.	0.7	8
49	Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e015761.	1.6	22
50	Risk Factors Associated With Ischemic Stroke in Japanese Patients With Nonvalvular Atrial Fibrillation. <i>JAMA Network Open</i> , 2020, 3, e202881.	2.8	39
51	Different Impact of Resting Heart Rate on Adverse Events in Paroxysmal and Sustained Atrial Fibrillation—The Fushimi AF Registry. <i>Circulation Journal</i> , 2020, 84, 2138-2147.	0.7	4
52	Oral Anticoagulant Use in Elderly Japanese Patients With Non-Valvular Atrial Fibrillation—Subanalysis of the ANAFIE Registry. <i>Circulation Reports</i> , 2020, 2, 552-559.	0.4	16
53	Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 35-42.	1.8	58
54	Age-Dependent Prognostic Impact of Paroxysmal Versus Sustained Atrial Fibrillation on the Incidence of Cardiac Death and Heart Failure Hospitalization (the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1420-1429.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Baseline Demographics and Clinical Characteristics in the All Nippon AF in the Elderly (ANAFIE) Registry. <i>Circulation Journal</i> , 2019, 83, 1538-1545.	0.7	42
56	Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1498-1507.	1.8	19
57	Guideline-Adherent Treatment for Stroke and Death in Atrial Fibrillation Patients From UK and Japanese AF Registries. <i>Circulation Journal</i> , 2019, 83, 2434-2442.	0.7	6
58	Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1103-1113.	13.9	342
59	Prospective observational study in elderly patients with non-valvular atrial fibrillation: Rationale and design of the All Nippon AF In the Elderly (ANAFIE) Registry. <i>Journal of Cardiology</i> , 2018, 72, 300-306.	0.8	29
60	Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): Protocol for a multicenter, prospective, randomized, open-label, parallel group study. <i>International Journal of Cardiology</i> , 2018, 265, 108-112.	0.8	24
61	VEGF and Mortality in Patients With Suspected or Known Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, e010355.	1.6	26
62	Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. <i>Stroke</i> , 2018, 49, 2301-2308.	1.0	68
63	Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation – The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 2983-2991.	0.7	16
64	Predictors of Cardioembolic Stroke in Japanese Patients with Atrial Fibrillation in the Fushimi AF Registry. <i>Cerebrovascular Diseases Extra</i> , 2018, 8, 50-59.	0.5	7
65	Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry. <i>Heart and Vessels</i> , 2018, 33, 1534-1546.	0.5	6
66	Incidence and Risk Factors of Stroke or Systemic Embolism in Patients With Atrial Fibrillation and Heart Failure – The Fushimi AF Registry. <i>Circulation Journal</i> , 2018, 82, 1327-1335.	0.7	27
67	Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). <i>American Journal of Cardiology</i> , 2017, 119, 1229-1237.	0.7	36
68	Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries. <i>EBioMedicine</i> , 2017, 18, 199-203.	2.7	18
69	Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. <i>American Heart Journal</i> , 2017, 194, 99-106.	1.2	36
70	Clinical Impact of Asymptomatic Presentation Status in Patients With Paroxysmal and Sustained Atrial Fibrillation. <i>Chest</i> , 2017, 152, 1266-1275.	0.4	30
71	Relationship of Hypertension and Systolic Blood Pressure With the Risk of Stroke or Bleeding in Patients With Atrial Fibrillation: The Fushimi AF Registry. <i>American Journal of Hypertension</i> , 2017, 30, 1073-1082.	1.0	44
72	Sex-Related Differences in the Clinical Events of Patients With Atrial Fibrillation – The Fushimi AF Registry. <i>Circulation Journal</i> , 2017, 81, 1403-1410.	0.7	17

#	ARTICLE	IF	CITATIONS
73	Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients—Fushimi AF Registry. <i>Circulation Journal</i> , 2017, 81, 1278-1285.	0.7	111
74	Stroke and death in elderly patients with atrial fibrillation in Japan compared with the United Kingdom. <i>Heart</i> , 2016, 102, 1878-1882.	1.2	18
75	Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation. <i>Chest</i> , 2016, 149, 401-412.	0.4	80
76	International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): Rationale, Design, and Initial Descriptives. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	18
77	Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. <i>Scientific Reports</i> , 2016, 6, 31042.	1.6	96
78	Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. <i>Heart and Vessels</i> , 2016, 31, 2025-2034.	0.5	13
79	Study design of J-ELD AF: A multicenter prospective cohort study to investigate the efficacy and safety of apixaban in Japanese elderly patients. <i>Journal of Cardiology</i> , 2016, 68, 554-558.	0.8	17
80	Indications, applications, and outcomes of inferior vena cava filters for venous thromboembolism in Japanese patients. <i>Heart and Vessels</i> , 2016, 31, 1084-1090.	0.5	8
81	Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure. <i>Heart and Vessels</i> , 2016, 31, 1154-1161.	0.5	14
82	Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients—Insight From the Fushimi AF Registry. <i>Circulation Journal</i> , 2015, 79, 1009-1017.	0.7	58
83	Incidence of Ischemic Stroke in Japanese Patients With Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>Circulation Journal</i> , 2015, 79, 432-438.	0.7	108
84	Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The Fushimi AF Registry. <i>PLoS ONE</i> , 2015, 10, e0142394.	1.1	27
85	Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 3354-3361.	1.0	100
86	Antiplatelet therapy in Japanese patients with atrial fibrillation without oral anticoagulants: Pooled analysis of Shinken Database, J-RHYTHM registry and Fushimi AF registry. <i>International Journal of Cardiology</i> , 2015, 190, 344-346.	0.8	3
87	Stroke prevention in atrial fibrillation: evidence from real-life studies: Table 1. <i>European Heart Journal Supplements</i> , 2015, 17, D42-D52.	0.0	4
88	Atrial fibrillation and coronary artery disease: Resembling twins?. <i>Journal of Cardiology</i> , 2014, 63, 169-170.	0.8	8
89	Serofendic Acid Protects Against Myocardial Ischemia—Reperfusion Injury in Rats. <i>Journal of Pharmacological Sciences</i> , 2014, 126, 274-280.	1.1	8
90	Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2014, 78, 2166-2172.	0.7	123

#	ARTICLE	IF	CITATIONS
91	Current status of clinical background of patients with atrial fibrillation in a community-based survey: The Fushimi AF Registry. <i>Journal of Cardiology</i> , 2013, 61, 260-266.	0.8	206
92	The targeting of cyclophilin D by RNAi as a novel cardioprotective therapy: evidence from two-photon imaging. <i>Cardiovascular Research</i> , 2009, 83, 335-344.	1.8	31
93	Serofendic Acid, a Substance Extracted from Fetal Calf Serum, as a Novel Drug for Cardioprotection. <i>Cardiovascular Drug Reviews</i> , 2007, 25, 333-341.	4.4	7
94	Serofendic Acid, a Novel Substance Extracted From Fetal Calf Serum, Protects Against Oxidative Stress in Neonatal Rat Cardiac Myocytes. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1882-1890.	1.2	26
95	Serofendic acid, a neuroprotective substance derived from fetal calf serum, inhibits mitochondrial membrane depolarization and caspase-3 activation. <i>European Journal of Pharmacology</i> , 2006, 542, 69-76.	1.7	23
96	Real-Time 2-Photon Imaging of Mitochondrial Function in Perfused Rat Hearts Subjected to Ischemia/Reperfusion. <i>Circulation</i> , 2006, 114, 1497-1503.	1.6	76
97	Uncoupling Protein-2 Overexpression Inhibits Mitochondrial Death Pathway in Cardiomyocytes. <i>Circulation Research</i> , 2003, 93, 192-200.	2.0	292
98	Nicorandil prevents oxidative stress-induced apoptosis in neurons by activating mitochondrial ATP-sensitive potassium channels. <i>Brain Research</i> , 2003, 990, 45-50.	1.1	45
99	Mechanistically Distinct Steps in the Mitochondrial Death Pathway Triggered by Oxidative Stress in Cardiac Myocytes. <i>Circulation Research</i> , 2003, 92, 186-194.	2.0	151
100	Mitochondrial ATP-Sensitive Potassium Channel Activation Protects Cerebellar Granule Neurons From Apoptosis Induced by Oxidative Stress. <i>Stroke</i> , 2003, 34, 1796-1802.	1.0	120
101	Differential Actions of Cardioprotective Agents on the Mitochondrial Death Pathway. <i>Circulation Research</i> , 2003, 92, 195-202.	2.0	78
102	Antiapoptotic effect of nicorandil mediated by mitochondrial atp-sensitive potassium channels in cultured cardiac myocytes. <i>Journal of the American College of Cardiology</i> , 2002, 40, 803-810.	1.2	98
103	Mitochondrial ATP-Sensitive Potassium Channels Inhibit Apoptosis Induced by Oxidative Stress in Cardiac Cells. <i>Circulation Research</i> , 2001, 88, 1267-1275.	2.0	255
104	Mitochondrial ATP-Sensitive Potassium Channels Attenuate Matrix Ca ²⁺ Overload During Simulated Ischemia and Reperfusion. <i>Circulation Research</i> , 2001, 89, 891-898.	2.0	348